U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356453) titled 'A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.' on Dec. 23, 2025.
Brief Summary: The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion Dose (RCED) of FORX-428 as monotherapy.
Study Start Date: July 22, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: FORX-428
FORX-428 drug product is formu...